FindTrial
Sign In

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-068-14
Enrollment
140
Registered
2015-02-11
Start date
2015-05-18
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Ver Protocolo, Seccion 7.1

Sponsors

ASTRAZENECA - PERU,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Ver Protocolo, Seccion 3.1

Exclusion criteria

Exclusion criteria: Ver Protocolo, Seccion 3.2

Countries

Argentina, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Germany, Hungary, India, Italy, Korea South, Mexico, Peru, Philippines, Poland, Romania, Russian Federation, Slovakia, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kindgdom, United States, Vietnam

Contacts

Public ContactUrsula Rodriguez-Frias

ASTRAZENECA PERU S.A.

ursula.rodriguezfrias@astrazeneca.com6101515

Outcome results

None listed

Source: REPEC (via WHO ICTRP)